Chapman Gina 4

What Happened Gina Chapman, a director of Entrada Therapeutics (TRDA), was granted a derivative award covering 19,000 shares on June 10, 2026. The transaction is reported as an award/grant (code A) and shows an acquired amount of 19,000 shares at $0.00 (derivative security). This is an equity grant rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-10; Form 4 filed 2026-06-12 (timely filing).
• Type: Award/Grant of derivative securities (code A); 19,000 shares reported at $0.00.
• Vesting/exercise: Per footnote, the shares become exercisable on the earlier of (i) the one-year anniversary of June 10, 2026, or (ii) the issuer’s next annual meeting of stockholders (Footnote F1).
• Shares owned after the transaction: Not specified in the filing.
• No 10b5-1 plan, tax-withholding, or late-filing flags noted in this Form 4.

Context This is a typical director equity grant: a derivative award that provides the right to acquire shares in the future once vesting/exercise conditions are met. Such grants are common as compensation for board service and do not represent an immediate market purchase or sale. The filing does not disclose a strike price or whether the award is an option vs. restricted stock unit; the footnote clarifies the vesting/exercise timing.